Case study reveals high variability in PSMA uptake in metastatic sarcoma, suggesting potential imaging applications and therapy options.
Immunohistochemical studies show PSMA may be a potential target for molecular imaging and treatment in bone and soft tissue sarcomas. We describe 68Ga-PSMA-11 PET/CT findings in a case with metastatic undifferentiated sarcoma. The sarcoma lesions showed a high variability of 68Ga-PSMA-11 uptake measured by SUVmax, ranging from 3.2 to 21.5. This case indicates that undifferentiated sarcoma can show increased PSMA uptake, 68Ga-PSMA-11 PET may noninvasively evaluate the inter-tumor heterogeneity of PSMA expression, and PSMA-targeted radioligand therapy may be a promising therapeutic option for this aggressive sarcoma.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: